Results 21 to 30 of about 6,015 (212)
Anesthesia in the surgery of strabismus: role of anesthetic agents in the ocular deviation and surgical outcome [PDF]
, 2015 Purpose: To determine whether the changes in the ocular alignment following general anesthesia, maintained with two different inhalational anesthetic agents, sevoflurane and desflurane, can be used as a predictor for surgical outcomes in children with ...
Arrico, Loredana +5 more
core +1 more source
Sugammadex: A neuromuscular blockade agent encapsulator
Southwest Respiratory and Critical Care Chronicles, 2017 Sugammadex sodium, a modified γ-cyclodextrin, represents a new class of drugs effective at reversing non-depolarizing muscle relaxants rocuronium and vecuronium.
Victoria Yepes Hurtado
doaj +1 more source
Delayed-Onset Malignant Hyperthermia in Association with Rocuronium Use [PDF]
, 2012 Purpose Two cases of malignant hyperthermia suspected to be related to the use of a nondepolarizing neuromuscular blocker are reported. Summary A pharmacogenetic disorder that may occur in as many as 1 in 3000 anesthesia procedures, malignant ...
Beggs, Ashton E. +2 more
core +2 more sources
Studies on fazadinium bromide (AH 8165): A new non-depolarizing neuromuscular blocking agent [PDF]
Canadian Anaesthetists’ Society Journal, 1976 Intravenous dose-response relationships were used to correlate neuromuscular paralysis with the effects of fazadinium (AH 8165) on autonomic mechanisms in anaesthetized cats and rhesus monkeys and with cardiovascular effects in man. In cats and monkeys neuromuscular paralysis of the twitch responses of the gastrocnemius muscle by fazadinium was ...
R, Hughes, J P, Payne, N, Sugai
openaire +2 more sources
A fresh look at paralytics in the critically ill: real promise and real concern. [PDF]
, 2012 Neuromuscular blocking agents (NMBAs), or "paralytics," often are deployed in the sickest patients in the intensive care unit (ICU) when usual care fails.
Kenyon, Nicholas J +2 more
core +2 more sources
BMC Anesthesiology, 2017 Sugammadex, a modified gamma-cyclodextrin, has changed clinical practice of neuromuscular reversal dramatically. With the introduction of this selective relaxant binding agent, rapid and reliable neuromuscular reversal from any depth of block became ...
Hajime Iwasaki +3 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Background: Sugammadex is known to reverse neuromuscular blockade induced by non-depolarizing agents. In children, the recommended dose for reversal of moderate neuromuscular blockade is 2 mg/kg.
Sang-Hwan Ji +17 more
doaj +1 more source
Sugammadex for reversal of neuromuscular blockade: A retrospective analysis of clinical outcomes and cost-effectiveness in a single center [PDF]
, 2016 OBJECTIVE: The aim of the study is to evaluate the clinical and economic impact of introducing a rocuronium-neostigmine-sugammadex strategy into a cisatracurium-neostigmine regimen for neuromuscular block (NMB) management.
BARATTO, FABIO +3 more
core +1 more source
Malignant hyperthermia – state of knowledge
Journal of Education, Health and Sport, 2022 Malignant hyperthermia (MH) is a relatively rare, but potentially lethal genetic disorder. That disease is characterized by hypermetabolic response of the skeletal muscles caused by exposure to triggering agents e.g. volatile anesthetics or depolarizing
Michał Perszke +6 more
doaj +1 more source
Neuronal effects of Sugammadex in combination with Rocuronium or Vecuronium. [PDF]
, 2017 Rocuronium (ROC) and Vecuronium (VEC) are the most currently used steroidal non-depolarizing neuromuscular blocking (MNB) agents. Sugammadex (SUG) rapidly reverses steroidal NMB agents after anaesthesia.
Aldasoro Celaya, Martín +10 more
core +1 more source